Preparation method of umbilical cord mesenchymal stem cell aging model

Through the induction of DNA damage by doxorubicin and etoposide, a premature umbilical cord mesenchymal stem cell aging model was prepared, which solved the problem of decreasing cell proliferation ability during in vitro expansion, achieved a stable cell aging model, and promoted drug development to maintain cell proliferation ability.

CN119020277APending Publication Date: 2024-11-26ZHEJIANG SIDAM STEM CELL BIOTECHNOLOGY CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411136423.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Human umbilical cord mesenchymal stem cells gradually lose their proliferative ability and therapeutic properties during in vitro expansion, resulting in genomic instability and cell aging, affecting their clinical application.

Method used

By inducing DNA damage and oxidative stress using doxorubicin and etoposide, a premature umbilical cord mesenchymal stem cell senescence model was prepared, and inducing induction conditions were screened using aging-related β-galactosidase activity detection method to induce cells into premature senescence. state, maintain the proliferation ability of cells.

Benefits of technology

A rapid and effective acquisition of stable umbilical cord mesenchymal stem cell aging model is achieved, and it is used to develop drugs that inhibit cell aging and maintain proliferation ability, avoiding the genomic instability caused by multiple passages.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020277A_ABST
    Figure CN119020277A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of an umbilical cord mesenchymal stem cell aging model, which comprises the following steps: treating umbilical cord mesenchymal stem cells by using adriamycin or etoposide; the activity of senescence-related beta-galactosidase, the protein expression of a cell cycle inhibition factor p21 and senescence cell markers such as gamma-H2A. X focus are respectively detected through enzyme activity staining, protein immunoblotting and immunofluorescence staining, and the result shows that when the umbilical cord mesenchymal stem cells are treated by the method disclosed by the invention, the activity of the senescence-related beta-galactosidase can be obviously improved; the activity of senescence-related beta-galactosidase in cells, p21 protein and gamma-H2A. X focus are all remarkably increased, which prompts that the umbilical cord mesenchymal stem cell senescence model is successfully established.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to an umbilical cord mesenchymal stem cell aging model and a preparation method thereof. Background Art

[0002] Human umbilical cord mesenchymal stem cells (hUC-MSCs) refer to a type of multifunctional stem cells present in the umbilical cord tissue of newborns, which have the functions of self-renewal, multidirectional differentiation and immunoregulation. First of all, hUC-MSCs can continuously self-renew and differentiate into one or more cell types under certain conditions, such as osteoblasts, chondrocytes and adipocytes, which then constitute the tissues and organs of the human body. hUC-MSCs cells themselves can also play an immunoregulatory function: intravenously injected hUC-MSCs can migrate to the site of injury and respond to inflammation. In addition, hUC-MSCs can also secrete a variety of bioactive factors through autocrine or paracrine secretion or through extracellular vesicles, such as exosomes and microvesicles, to respond to local microenvironment or signals. Compared with other stem cells, hUC-MSCs have the advantages of being easier to obtain, separate, culture, amplify and purify. And hUC-MSCs have low immunogenicity, so they have more unique advantages in clinical applications. In addition, compared with traditional treatments, hUC-MSCs can not only improve the survival rate, but also significantly improve the various clinical symptoms of the disease. In summary, hUC-MSCs has become one of the important sources of stem cells in cell therapy and regenerative medicine.

[0003] There is increasing evidence that hUC-MSCs have advantages in treating a variety of diseases. However, hUC-MSCs will gradually lose their proliferation ability and therapeutic properties after in vitro expansion. hUC-MSCs can be cultured multiple times and subcultured to obtain a large number of cells. However, during long-term culture, abnormalities in pathways related to the cell cycle and DNA damage response can lead to genomic instability in hUC-MSCs, and in the later stages of subculture, the cell morphology becomes longer and larger, proliferation slows, and proliferation-related genes decrease. The aging of hUC-MSCs will affect their clinical application. For example, in the treatment of acute liver failure, the 5th generation cells are more effective than the 10th generation cells in homing to the liver, enhancing liver cell proliferation, and inhibiting apoptosis. And the elimination of senescent cells can promote stem cell proliferation and delay the appearance of aging characteristics. Summary of the invention

[0004] In view of the deficiencies in the prior art, the present invention provides a premature umbilical cord mesenchymal stem cell aging model induced by stresses such as DNA damage and oxidative stress and a preparation method thereof.

[0005] The specific technical solutions of the present invention are as follows:

[0006] A method for preparing an umbilical cord mesenchymal stem cell aging model comprises treating hUC-MSCs cells with a cell growth density of 60% to 70% with 0.05-0.25 μM doxorubicin for 24-48 hours and then resuming culture for 6-7 days; or treating hUC-MSCs cells with 4-20 μM etoposide for 24-72 hours and then resuming culture for 4-7 days.

[0007] A preferred solution of the present invention is to treat with 0.05 μM doxorubicin for 48 hours and then recover the culture for 6 days; or to treat with 10 μM etoposide for 24 hours and then recover the culture for 7 days.

[0008] The method of the present invention specifically comprises taking hUC-MSCs with a cell growth density of 60% to 70%, discarding the culture medium, adding fresh culture medium containing doxorubicin or etoposide, culturing at 37°C in a carbon dioxide cell culture incubator for a corresponding drug treatment time, discarding the culture medium containing the drug, adding fresh complete cell culture medium, and continuing to place in a carbon dioxide cell culture incubator for recovery culture before collecting the cells.

[0009] The culture medium used in the method of the present invention is DMEM / F12 culture medium containing 10% fetal bovine serum.

[0010] Another object of the present invention is to provide an umbilical cord mesenchymal stem cell aging model prepared by the method described in the present invention.

[0011] Advantages of the present invention:

[0012] The present invention uses the senescence-associated β-galactosidase (SA-β-gal) activity detection method to screen the types of senescence-inducing drugs and induction conditions, and determines that doxorubicin and etoposide can be used as drug inducers for inducing premature senescence of hUC-MSCs by external pressure. The present invention detects the expression changes of the senescence cell marker cell cycle inhibitor p21 protein in hUC-MSCs treated with doxorubicin and etoposide by protein immunoblotting (Western Blot, WB), and finds that the expression of p21 in senescent cells is increased. By immunofluorescence (Immunofluorescence, IF) staining to detect the changes in γ-H2A.X foci in drug-induced senescent cells, it is found that the DNA damage in senescent cells is also significantly increased. The above results show that doxorubicin and etoposide can effectively induce hUC-MSCs to undergo premature senescence.

[0013] The present invention can quickly and effectively obtain a stable umbilical cord mesenchymal stem cell aging model through drug induction without multiple passages, and can be applied to the development of drugs that inhibit hUC-MSCs cell aging and maintain their in vitro proliferation ability. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 Results of SA-β-gal activity detection of hUC-MSCs passage cells. (A) SA-β-gal staining results. (B) Statistical graph of SA-β-gal activity detection results.

[0015] Figure 2 Results of the SA-β-gal activity test of hUC-MSCs senescent cells induced by doxorubicin. (A) SA-β-gal staining results. (B) Statistical graph of SA-β-gal activity test results.

[0016] Figure 3 Results of the SA-β-gal activity test of hUC-MSCs senescent cells induced by etoposide. (A) SA-β-gal staining results. (B) Statistical graph of SA-β-gal activity test results.

[0017] Figure 4 Results of the SA-β-gal activity test of hUC-MSCs senescent cells induced by Bleomycin. (A) Results of SA-β-gal staining. (B) Statistical graph of SA-β-gal activity test results.

[0018] Figure 5 The results of SA-β-gal staining of hUC-MSCs senescent cells induced by atazanavir / ritonavir.

[0019] Figure 6 The cytotoxic effects of doxorubicin and etoposide on hUC-MSCs.

[0020] Figure 7 The expression changes of p21 protein in hUC-MSCs after senescence induced by doxorubicin and etoposide (A) Western blotting results. (B) Semi-quantitative analysis of Western blotting results.

[0021] Figure 8 Immunofluorescence staining was used to detect the expression changes of γ-H2A.X foci in the nucleus of hUC-MSCs after senescence induced by doxorubicin or etoposide. (A) γ-H2A.X foci staining results (green). Scale bar: 20 μm. (B) Statistical graph of immunofluorescence staining results. DETAILED DESCRIPTION

[0022] The specific steps of the present invention are described below by way of examples, but are not limited to the examples.

[0023] The terms used in the present invention, unless otherwise specified, generally have the meanings commonly understood by those of ordinary skill in the art.

[0024] The present invention will be further described in detail below in conjunction with specific examples and with reference to data. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention in any way.

[0025] In the following examples, various processes and methods not exhaustively described are conventional methods well known in the art.

[0026] Example 1 Isolation and preparation of hUC-MSCs

[0027] 1. Take a fresh umbilical cord, clean the surface of the umbilical cord with PBS containing double antibodies, and squeeze out the residual blood in the blood vessels;

[0028] 2. Use sterile surgical scissors to cut off both ends of the umbilical cord and cut the remaining part into small pieces of 2-3 cm in length;

[0029] 3. Continue to wash the umbilical cord with PBS and use tweezers to clean the blood in the umbilical cord;

[0030] 4. Use forceps to peel off the umbilical cord tissue, use hooked forceps to gently tear off the vein, then tear off the artery, then wash it 3 times with PBS, and cut it into pieces in a 50mL centrifuge tube;

[0031] 5. Digest with 0.1% collagenase and hyaluronidase for 3-4 hours, filter, and centrifuge 2-3 times;

[0032] 6. Transfer the cells into a culture flask, spread them evenly, and use DMEM / F12 (1:1) culture medium (Shanghai Yuanpei Biotechnology Co., Ltd.) containing 10% fetal bovine serum for adherent subculture.

[0033] Example 2 Preparation of hUC-MSCs aging model

[0034] 1. Inoculate hUC-MSCs into a 6-well plate and observe under a microscope. When the cell growth density reaches about 60% to 70%, senescence induction can be performed;

[0035] 2. Take out the cell culture dish, discard the culture medium, wash once with 1× PBS buffer, and add fresh culture medium. Refer to the table below to add a certain concentration of doxorubicin, etoposide, bleomycin, atazanavir / ritonavir to the cells, and gently shake the cell culture dish up and down to mix evenly; move to a carbon dioxide cell culture incubator to culture for a certain period of drug-induced senescence, discard the medium containing drugs, and add fresh complete cell culture medium. Continue to place in the carbon dioxide cell culture incubator to resume culture.

[0036]

[0037]

[0038] Example 3 SA-β-gal staining experiment of senescent cells

[0039] hUC-MSCs cells that were passaged normally for multiple times and the groups of hUC-MSCs senescent cells constructed in Example 2 were used as research objects. The senescence of hUC-MSCs in each group was detected using a SA-β-gal staining kit. The cells were observed and photographed under a total internal reflection fluorescence microscope, and the number of stained cells in each group was counted. Figure 1-5 As shown. The results showed that the efficiency and cytotoxicity of the above candidate senescence inducers in inducing hUC-MSC senescence were different, among which 0.05μM doxorubicin treatment for 48h and recovery for 6 days or 10μM etoposide treatment for 24h and recovery for 7 days had the most obvious effect on inducing cell senescence. However, bleomycin had a poor effect on inducing cell senescence, and the number of cells after treatment was significantly reduced compared with doxorubicin and etoposide, suggesting that bleomycin may cause more hUC-MSCs to die rather than age due to cytotoxicity. There was no significant change in the efficiency of 25μM atazanavir / ritonavir inducing hUC-MSCs senescence compared with the control group.

[0040] Example 4 Cell Viability Detection-CCK8 Method

[0041] Detection Example 2: After treatment with doxorubicin or etoposide and recovery of cell viability in each group of cells, 10 μL of CCK8 was added to each well, and the cells were cultured in a cell culture incubator for 2 hours. The 96-well plate was placed in an ELISA reader and shaken for 30 seconds, and the absorbance was detected at a wavelength of 450 nm. The data was collated and analyzed. Figure 6 The results showed that the cytotoxicity was lower when 0.05 μM doxorubicin was treated for 48 h and then recovered for 6 days. The cytotoxicity was lowest when 10 μM etoposide was treated for 24 h and then recovered for 7 days.

[0042] Example 5 Protein immunoblotting and immunofluorescence staining experiments

[0043] The hUC-MSCs senescent cells in each group of adriamycin or etoposide constructed in Example 2 were used as research objects, and the total protein of each group of cells was extracted. The expression changes of the senescent cell marker cell cycle inhibitor p21 protein in the senescent cells induced by adriamycin or etoposide were detected by Western blotting. The results are as follows Figure 7 Immunofluorescence staining was used to detect changes in γ-H2A.X foci in drug-induced senescent cells. Figure 8 The results showed that when doxorubicin and etoposide induced hUC-MSCs to undergo premature senescence, the p21 protein and γ-H2A.X foci in senescent cells were significantly upregulated.

Claims

1. A method for preparing an umbilical cord mesenchymal stem cell aging model, Features Umbilical cord mesenchymal stem cells with a cell growth density of 60% to 70% are treated with 0.05-0.25 μM doxorubicin for 24-48 hours and then resumed for 6-7 days; or treated with 4-20 μM etoposide for 24-72 hours and then resumed for 4-7 days.

2. The method according to claim 1, Features After treatment with 0.05 μM doxorubicin for 48 h, the culture was restored for 6 days; Alternatively, cells were treated with 10 μM etoposide for 24 h and recovered for 7 days.

3. The method according to claim 1 or 2, Features The method specifically comprises taking umbilical cord mesenchymal stem cells with a cell growth density of 60% to 70%, discarding the culture medium, adding fresh culture medium containing doxorubicin or etoposide, culturing at 37°C in a carbon dioxide cell culture incubator for a corresponding drug treatment time, discarding the culture medium containing the drug, adding fresh complete cell culture medium, continuing to place in a carbon dioxide cell culture incubator for recovery culture, and then collecting the cells.

4. The method according to claim 3, Features The culture medium is DMEM / F12 culture medium containing 10% fetal bovine serum.

5. An umbilical cord mesenchymal stem cell aging model, Features The method is prepared by any one of claims 1 to 4.

Citation Information

Cited By

  • Anti-aging compound as well as preparation method and application thereof

    CN122255078A